446 related articles for article (PubMed ID: 25446815)
1. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.
Ohno A; Yorita K; Haruyama Y; Kondo K; Kato A; Ohtomo T; Kawaguchi M; Marutuska K; Chijiiwa K; Kataoka H
Liver Int; 2014 Jul; 34(6):942-52. PubMed ID: 24433439
[TBL] [Abstract][Full Text] [Related]
3. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.
Chen HL; OuYang HY; Le Y; Jiang P; Tang H; Yu ZS; He MK; Tang YQ; Shi M
Cancer Med; 2018 Nov; 7(11):5339-5350. PubMed ID: 30306706
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
Cheng B; Chen X; Li Y; Huang X; Yu J
Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
[TBL] [Abstract][Full Text] [Related]
5. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
[TBL] [Abstract][Full Text] [Related]
6. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
7. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
9. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
11. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
12. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
13. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
[TBL] [Abstract][Full Text] [Related]
15. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
[TBL] [Abstract][Full Text] [Related]
16. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
19. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients.
Zhu J; Wu YN; Zhang W; Zhang XM; Ding X; Li HQ; Geng M; Xie ZQ; Wu HM
PLoS One; 2014; 9(1):e87904. PubMed ID: 24498219
[TBL] [Abstract][Full Text] [Related]
20. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.
Wang JH; Zhong XP; Zhang YF; Wu XL; Li SH; Jian PE; Ling YH; Shi M; Chen MS; Wei W; Guo RP
Cell Death Dis; 2017 Sep; 8(9):e3043. PubMed ID: 28880268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
